Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
2011

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Sample size: 95 publication Evidence: high

Author Information

Author(s): Castillo-Trivino Tamara, Mowry Ellen M., Gajofatto Alberto, Chabas Dorothee, Crabtree-Hartman Elizabeth, Cree Bruce A., Goodin Douglas S., Green Ari J., Okuda Darin T., Pelletier Daniel, Zamvil Scott S., Vittinghoff Eric, Waubant Emmanuelle

Primary Institution: University of California San Francisco

Hypothesis

The effect of natalizumab monotherapy in patients with breakthrough disease is unknown.

Conclusion

Switching to natalizumab or immunosuppressants in patients with breakthrough disease is effective in reducing clinical activity of relapsing MS.

Supporting Evidence

  • Relapse rate decreased by 70% in switchers to natalizumab.
  • Relapse rate decreased by 77% in switchers to immunosuppressants.
  • Relapse rate in non-switchers did not decrease.

Takeaway

If people with multiple sclerosis are not doing well on their first medicine, switching to a different medicine can help them feel better.

Methodology

This is an open-label retrospective cohort study of 993 patients seen at least four times at the UCSF MS Center.

Potential Biases

Differences in the groups that led to a different response to second-line therapies may exist.

Limitations

The treatment assignment was not randomized, which may lead to differences in response to therapies.

Participant Demographics

Patients included had relapsing-remitting or relapsing secondary progressive MS.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 50,82%

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016664

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication